AcelRx Pharma (ACRX) to Present ARX-04 Data at ECEM 2016
- Wall Street dips as telecoms slump; AmEx surges
- Microsoft (MSFT) Tops Q1 EPS by 8c
- AMD (AMD) Posts Q3 Operating EPS of 3c; Sees Q4 Revenue Down Sequentially
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- After-Hours Stock Movers 10/20: (CERC) (ALKS) (PFPT) (MSFT) Higher; (SKX) (RRGB) (AMD) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), which is being held October 1-5, 2016 in Vienna, Austria. Both e-posters will be displayed on monitors throughout the meeting, and will be available following the conclusion of the conference on the AcelRx Publications webpage.
The first presentation summarizes the safety and efficacy findings from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in patients who were admitted to the emergency department with an injury or trauma associated with moderate-to-severe acute pain. Results from this trial showed substantial reductions in pain intensity (mean 2.9 out of 10 on a validated pain scale) within the first hour among the 76 patients treated with ARX-04. The second e-poster provides insights into the direct and indirect (labor, pharmacy, etc.) costs associated with the administration of intravenous (IV) opioids. Based on an analysis of over 600 hospitals, AcelRx has determined that an initial IV dose of an opioid, such as morphine, hydromorphone and fentanyl, ranges from $143 to $145 in U.S. emergency departments.
Details on the presentations are as follows:
Efficacy and Safety of Sufentanil Sublingual Tablet 30 mcg for Management of Acute Traumatic Pain in the Emergency Department
James Miner, MD of the Hennepin County Medical Center in Minneapolis, MN; Harold Minkowitz, MD of the Memorial Hermann Memorial City Medical Center in Houston, TX; Zubaid Rafique, MD of Baylor College of Medicine in Houston, TX; and Karen DiDonato, MSN, RN and Pamela Palmer, MD, PhD of AcelRx Pharmaceuticals
Cost of Delivering Intravenous Opioid Analgesia in Emergency Departments in the United States
Pamela P. Palmer, MD PhD, Brenda Lemus, MD, and Karen DiDonato, MSN, RN of AcelRx Pharmaceuticals; and John House, MS of Premier, Inc.
ECEM is the annual meeting of the European Society for Emergency Medicine, which represents 33 European national emergency medicine societies. The Society strives to advance research, education, practice and standards of the specialty of emergency medicine throughout Europe. More information on the Society may be found at www.eusem.org.
Clinical and Rehabilitative Medicine Research Program (CRMRP)ARX-04 is funded in part by the Clinical and Rehabilitative Medicine Research Program (CRMRP) of the U.S. Army Medical Research and Materiel Command (USAMRMC) under contract No. W81XWH-15-C-0046. The CRMRP was established in 2008 to foster research and technology advances for regeneration, restoration, and rehabilitation of traumatic injuries.
In accordance with USAMRMC guidelines, in the conduct of clinical research, AcelRx has adhered to the policies regarding the protection of human subjects as prescribed by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter 1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Whole Foods Market (WFM) Says It's Cooperating Fully with Detroit Health Department Following Case of Hepatitis A
- FMC Technologies (FTI) Enters Settlement with U.S. SEC Over Allegations of Overstated Profits; Will Pay Penalty
- Martin Midstream Partners (MMLP) to Divest Corpus Christi Terminalling Assets for Net Proceeds of $93M
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!